Becton Dickinson (NYSE: BDX) reported Q2 EPS of $3.19, $0.15 better than the analyst estimate of $3.04. Revenue for the quarter came in at $4.9 billion versus the consensus estimate of $4.88 billion.

GUIDANCE:

Becton Dickinson sees FY2021 EPS of $12.75-$12.85, versus the consensus of $12.84.

• The COVID-19 pandemic continues to impact the global economy and health care utilization trends. The company's fiscal 2021 outlook includes several assumptions, including no significant change in utilization or procedure volumes associated with COVID-19 resurgences. Management will discuss its outlook and several assumptions on its second fiscal quarter earnings call.
• The company continues to expect fiscal year 2021 revenues to grow 12% to 14% on an as reported basis and 10% to 12% on a currency-neutral basis. Foreign currency is expected to contribute approximately 200 basis points to revenue growth.
• The company continues to expect fiscal year 2021 adjusted diluted EPS to be between $12.75 and $12.85. This adjusted EPS guidance range represents growth of approximately 25% to 26% over fiscal 2020 adjusted diluted EPS of $10.20, and includes a contribution of approximately 100 basis points from foreign currency. On a currency-neutral basis, the company continues to expect adjusted diluted EPS to grow 24% to 25%.

For earnings history and earnings-related data on Becton Dickinson (BDX) click here.